An interventional study of NAVIGATE in Lung Cancer, sponsored by Zealand University Hospital. Recruiting at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Zealand University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.
Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 36th largest by planned enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2022, is one of 46 with no phase, reaches primary completion later than 17 of the 46 other live ones, and was the 83rd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
Aarhus University Hospital · Sites in Denmark
Ages 18+
Vejle Hospital · Sites in Denmark
Ages 50+
Vejle Hospital · Sites in Denmark
Ages 50+
Ditte Krag-Hansen · Sites in Denmark
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 1998; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 158 across the 94 interventional studies, 105 across the 30 observational. Of the 60 that completed or were terminated, 12 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 124 have an industry lead sponsor. The 10 most frequent:
Zealand University Hospital is the lead sponsor of 237 studies on the registry; 50 are open to participants now.
Zealand University Hospital has 4 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Lung Neoplasms with a site in Denmark that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06537804Odense University HospitalProject Lung Cancer Screening in Southern Denmark | 2026-12-31 |
| NCT05053997Zealand University HospitalNavigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients | 2026-12-31 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
Add all 12 to your calendar (.ics) → With an account.
Among the 124 studies in Lung Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first line treatment as planned either due to poor performance status or if they are not able to adhere to treatment appointments. Knowing how to navigate the health system may be a barrier preventing vulnerable patients in receiving optimal treatment. The primary aim of this randomised, controlled trial is to test whether a nurse-led individually tailored program including systematic screening of symptoms using PROs and a physical training program will significantly improve a composite outcome of survival and quality of life as the primary outcome among vulnerable lung cancer patients compared with standard care. Secondary outcomes include adherence to cancer treatment, symptom burden and overall survival.
During a period of 3 years and 10 months, consecutive newly diagnosed (\< 1 week) lung cancer patients will be pre-screened for eligibility and invited to participate at departments of oncology or respiratory medicine in Denmark. Participants (N=250) will be randomized (1:1) to standard treatment plus the intervention (intervention group) or standard treatment (control group) and followed for 1 year. Patients randomized to the control group will receive standard treatment and care consisting of a nurse and a physician, who sees the patient at treatment schedules and during follow-up, i.e. every 3 months for the first 2 years and subsequently annually up to 5 years.
Data will be collected from the intervention and the control group at baseline within 6 weeks after diagnosis, and 3, 6 months and 12 months after diagnosis. Physical tests will be performed at baseline and after 3 and 6 months. Baseline physical tests will be allowed after randomization if patients have difficulties in attending the physiotherapy department within 6 weeks after their diagnosis. Considering that participating patients are vulnerable with limited resources we will proactively support patients in responding to questionnaires electronically, on paper or via telephone as per patient's preference allowing evaluation of the primary and secondary outcomes as well as covariates and mechanisms. The treatment factors will be obtained from the lung cancer clinical database and individual medical journals. In order to develop cost utility analyses, information on use of health services will be retrieved from the national registers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nurse navigation
Behavioral: NAVIGATE
Standard treatment and care
Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
A hierarchical composite outcome of survival and global quality of life
Measured from death from all causes and the Global Health Status (a subscale of EORTC QLQ-C30)
Time frame: 3 months from randomization
Overall survival
Measured by death from all causes
Time frame: 3 months from randomization
Overall survival
Measured by death from all causes
Time frame: 6 months from randomization
Overall survival
Measured from death from all causes
Time frame: 12 months from randomization
Adherence to cancer treatment
Measured by date of skipped treatments or delays if any, and dose administered
Time frame: 3 months from randomization
Adherence to cancer treatment
Measured by date of skipped treatments or delays if any, and dose administered
Time frame: 6 months from randomization
Adherence to cancer treatment
Measured by date of skipped treatments or delays if any, and dose administered
Time frame: 12 months from randomization
Symptom burden and health related quality of life
Measured by EORTC Questionnaire Core 30 (QLQ-C30) and the lung module (QLQ-LC13). The QLQ-C30 questionnaire consists of 30 questions with five functional scales (physical, role, cognitive, emotional and social), three symptom scales, a global health status / QoL scale, and six single items. The QLQ-LC13 module comprises both multi-item and single-item measures of lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (hair loss,neuropathy, sore mouth and dysphagia). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: 3 months from randomization
Symptom burden and health related quality of life
Measured by EORTC Questionnaire Core 30 (QLQ-C30) and the lung module (QLQ-LC13). The QLQ-C30 questionnaire consists of 30 questions with five functional scales (physical, role, cognitive, emotional and social), three symptom scales, a global health status / QoL scale, and six single items. The QLQ-LC13 module comprises both multi-item and single-item measures of lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (hair loss, neuropathy, sore mouth and dysphagia). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: 6 months from randomization
Symptom burden and health related quality of life
Measured by EORTC Questionnaire Core 30 (QLQ-C30) and the lung module (QLQ-LC13). The QLQ-C30 questionnaire consists of 30 questions with five functional scales (physical, role, cognitive, emotional and social), three symptom scales, a global health status / QoL scale, and six single items. The QLQ-LC13 module comprises both multi-item and single-item measures of lung cancer-associated symptoms (coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (hair loss,neuropathy, sore mouth and dysphagia). All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.
Time frame: 12 months from randomization
Quality of life (QOL) measured by EuroQol EQ-5D-5L
EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.
Time frame: 3 months from randomization
Quality of life (QOL) measured by EuroQol EQ-5D-5L
EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.
Time frame: 6 months from randomization
Quality of life (QOL) measured by EuroQol EQ-5D-5L
EQ-5D-5L measures individual generic health status using 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each dimension has 5 levels depending on severity of symptoms (1 no problems, 5 extreme problems) and a VAS (visual analogue scale). The scores can then be converted into a single index number. The index value will be used for calculation of quality-adjusted life years (QALYs) for a health economic analysis of the intervention.
Time frame: 12 months from randomization
Health behavior
Measured by single-items questions related to physical activity, alcohol consumption and smoking behavior
Time frame: 3 months from randomization
Health behavior
Measured by single-items questions related to physical activity, alcohol consumption and smoking behavior.
Time frame: 6 months from randomization
Health behavior
Measured by single-items questions related to physical activity, alcohol consumption and smoking behavior.
Time frame: 12 months from randomization
Self-efficacy and self-activation
Measured by single items from Patient Activation Measure (PAM) and Health Education Impact Questionnaire (HEIQ)
Time frame: 3 months from randomization
Self-efficacy and self-activation
Measured by single items from Patient Activation Measure (PAM) and Health Education Impact Questionnaire (HEIQ)
Time frame: 6 months from randomization
Self-efficacy and self-activation
Measured by single items from Patient Activation Measure (PAM) and Health Education Impact Questionnaire (HEIQ)
Time frame: 12 months from randomization
Rehabilitation services
Measured by single item question
Time frame: 3 months from randomization
Rehabilitation services
Measured by single item question
Time frame: 6 months from randomization
Rehabilitation services
Measured by single item question
Time frame: 12 months from randomization
Process evaluation
Evaluation by participant-observations during training and patient sessions with subsequent qualitative semi-structured interviews with participants about their experience of the intervention components; however, only among participants who provide informed consent for this. Focus group interviews with nurse navigators and physiotherapists will be conducted about their perceptions of the intervention (facilitators and barriers). Additionally, evaluation of intervention components will be measured using quantitative single-items questions
Time frame: 3 months from evaluation
Process evaluation
Evaluation by participant-observations during training and patient sessions with subsequent qualitative semi-structured interviews with participants about their experience of the intervention components; however, only among participants who provide informed consent for this. Focus group interviews with nurse navigators and physiotherapists will be conducted about their perceptions of the intervention (facilitators and barriers). Additionally, evaluation of intervention components will be measured using quantitative single-items questions.
Time frame: 12 months from evaluation
Cost-effectiveness
Evaluation by health care costs and QALYs (Quality Adjusted Life Years) between the two groups.
Time frame: 12 months from randomization
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Mar 2022 (actual). Primary completion is estimated for Dec 2026, 57 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 57 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.